Vision One Management Partners LP Takes Position in The Chemours Company (NYSE:CC)

Vision One Management Partners LP bought a new stake in shares of The Chemours Company (NYSE:CC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,390,350 shares of the specialty chemicals company's stock, valued at approximately $28,252,000. Chemours accounts for about 19.2% of Vision One Management Partners LP's holdings, making the stock its 2nd largest holding. Vision One Management Partners LP owned 0.93% of Chemours as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Appian Way Asset Management LP bought a new stake in Chemours during the 3rd quarter valued at approximately $34,151,000. Marshall Wace LLP boosted its position in shares of Chemours by 23.8% during the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company's stock valued at $158,213,000 after purchasing an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC grew its stake in Chemours by 54.6% in the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company's stock worth $78,016,000 after purchasing an additional 1,220,967 shares during the period. Scopia Capital Management LP bought a new position in Chemours in the third quarter worth $13,623,000. Finally, FMR LLC grew its position in shares of Chemours by 3.5% in the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company's stock worth $368,650,000 after buying an additional 618,361 shares during the period. Institutional investors own 76.26% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CC. The Goldman Sachs Group cut their target price on Chemours from $29.00 to $23.00 and set a "neutral" rating on the stock in a research note on Tuesday, September 3rd. BMO Capital Markets lifted their target price on shares of Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Morgan Stanley cut their price target on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 5th. Barclays boosted their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada cut their target price on Chemours from $28.00 to $25.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Chemours presently has an average rating of "Hold" and a consensus target price of $24.88.

Insider Activity

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares of the company's stock, valued at $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.47% of the company's stock.

Chemours Stock Performance

Shares of CC traded down $0.10 on Friday, reaching $21.00. The company's stock had a trading volume of 1,208,958 shares, compared to its average volume of 1,341,558. The stock's 50 day simple moving average is $19.88 and its two-hundred day simple moving average is $21.08. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The stock has a market capitalization of $3.14 billion, a P/E ratio of 42.00 and a beta of 1.80. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $32.70.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.44 billion. During the same quarter last year, the company posted $0.64 EPS. The company's revenue was up .9% compared to the same quarter last year. Research analysts forecast that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 4.76%. The ex-dividend date of this dividend is Friday, November 15th. Chemours's dividend payout ratio (DPR) is currently 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.